علاج سرطان الدم الليمفاوي المزمن مع فقر الدم الانحلالي المناعي الذاتي أو قلة الصفيحات المناعية

References

Autoimmune haemolytic anaemia (AIHA) and, to a lesser extent, immune thrombocytopenia (ITP), are relatively frequent in CLL (5%–7%).

CLL patients with simple AIC should be managed in the same way as patients with primary AIHA or ITP (GRADE 1D).

For patients not responding to corticosteroids, rituximab monotherapy and/or thrombopoietin agonists in the case of ITP (e.g. romiplostim, eltromboplag, avatrombopag) are recommended second-line options.

For refractory cases, complement inhibition with sutimlimab (anti-C1S monoclonal antibody) is an effective option.

View source ↗